首页 文献索引 SCI期刊 AI助手
期刊目录筛选

期刊名:Cancer drug resistance

缩写:CANCER DRUG RESIST

ISSN:N/A

e-ISSN:2578-532X

IF/分区:5.2/Q1

文章目录 更多期刊信息

共收录本刊相关文章索引472
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
Caterina Perfetto,Marianna Aprile,Simona Cataldi et al. Caterina Perfetto et al.
Aim: As intrinsic resistance - often driven by concurrent genomic alterations in tumor suppressor genes or oncogenes - remains a major challenge in oncology, this work aimed to comprehensively analyze BRAF somatic alterations across cancer ...
Émilie Audrey Larose,Xinying Hua,Silin Yu et al. Émilie Audrey Larose et al.
Antibody-drug conjugates (ADCs) are a transformative approach in breast cancer therapy, offering targeted treatment with reduced toxicity by selectively delivering cytotoxic agents to cancer cells. While ADCs like trastuzumab emtansine (T-D...
Leyi Yao,Baoyi Jiang,Dacai Xu Leyi Yao
Cancer cells often develop tolerance to chemotherapy, targeted therapy, and immunotherapy drugs either before or during treatment. The significant heterogeneity among various tumors poses a critical challenge in modern cancer research, part...
Chi Teng,Jia-Wen Chen,Li-Sha Shen et al. Chi Teng et al.
Cancer remains a significant global health challenge, with current chemotherapeutic strategies frequently limited by the emergence of resistance. In this context, natural compounds with the potential to overcome resistance have garnered con...
Yi-Zhe Zhang,Yunshu Ma,Ensi Ma et al. Yi-Zhe Zhang et al.
Hepatocellular carcinoma (HCC) remains a serious threat to global health, with rising incidence and mortality rates. Therapeutic options for advanced HCC are quite limited, and the overall prognosis remains poor. Recent advancements in immu...
Chahat Suri,Babita Pande,Lakkakula Suhasini Sahithi et al. Chahat Suri et al.
Metabolic reprogramming within the tumor microenvironment (TME) plays a critical role in driving drug resistance in gastrointestinal cancers (GI), particularly through the pathways of fatty acid oxidation and glycolysis. Cancer cells often ...
Adam Khorasanchi,Feng Hong,Yuanquan Yang et al. Adam Khorasanchi et al.
Metastatic castration-resistant prostate cancer (mCRPC) is driven by a complex network of resistance mechanisms against standard-of-care therapies, resulting in poor long-term outcomes. This review offers a uniquely comprehensive and integr...
Yu-Qing Chen,Jia-Xiong Tan,Ling-Ling Gao et al. Yu-Qing Chen et al.
Aim: Small-cell lung cancer (SCLC) is usually diagnosed as an advanced stage with a poor outcome. SCLC has limited response to immunotherapy due to the absence or lack of immune cell infiltration, so studying its tumor immune microenvironme...
Bernhard Biersack,Bianca Nitzsche,Michael Höpfner Bernhard Biersack
Small-molecule BRAF inhibitors (e.g., vemurafenib and dabrafenib) and MEK (MAPK/ERK) kinases inhibitors (e.g., trametinib) have distinctly improved the survival of patients suffering from BRAF-mutant cancers such as melanomas. However, the ...
Yang Yang,Simin Yu,Wanyao Liu et al. Yang Yang et al.
Ferroptosis is an iron-dependent form of programmed cell death induced by lipid peroxidation. This process is regulated by signaling pathways associated with redox balance, iron metabolism, and lipid metabolism. Cancer cells' increased iron...